LHCGR-related Disorders via the LHCGR Gene
Summary and Pricing 
Test Method
Sequencing and CNV Detection via NextGen Sequencing using PG-Select Capture ProbesTest Code | Test Copy Genes | Test CPT Code | Gene CPT Codes Copy CPT Code | Base Price | |
---|---|---|---|---|---|
7729 | LHCGR | 81406 | 81406,81479 | $990 | Order Options and Pricing |
Pricing Comments
Testing run on PG-select capture probes includes CNV analysis for the gene(s) on the panel but does not permit the optional add on of exome-wide CNV analysis. Any of the NGS platforms allow reflex to other clinically relevant genes, up to whole exome or whole genome sequencing depending upon the base platform selected for the initial test.
An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.
This test is also offered via a custom panel (click here) on our exome or genome backbone which permits the optional add on of exome-wide CNV or genome-wide SV analysis.
Turnaround Time
3 weeks on average for standard orders or 2 weeks on average for STAT orders.
Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.
Targeted Testing
For ordering sequencing of targeted known variants, go to our Targeted Variants page.
Clinical Features and Genetics 
Clinical Features
The LHCGR gene encodes the receptor for both luteinizing hormone (LH) and choriogonadotropin (CG). Activating LHCGR pathogenic variants cause familial male precocious puberty while inactivating LHCGR pathogenic variants cause Leydig cell hypoplasia (LCH) in both males and females.
Familial male precocious puberty is a gonadotropin-independent disorder. Affected males generally exhibit signs of puberty by 4 years old (Shenker et al. 1993). This disease is inherited in an autosomal dominant manner, but is limited to males.
Leydig cell hypoplasia in 46, XY males has been classified into two types. Type I is characterized by complete 46,XY male pseudohermaphroditism, absent development of secondary male sex characteristics, low testosterone and high LH levels, total lack of responsiveness to LH/CG challenge, and lack of breast development due to complete inactivation of LHCGR. Type II presents a wide phenotypic range from micropenis to severe hypospadias due to partial inactivation of LHCGR (Themmen and Huhtaniemi 2000).
Leydig cell hypoplasia in 46, XX females leads to milder features characterized by amenorrhea, defective follicular development and ovulation, and infertility (Themmen and Huhtaniemi 2000).
Genetics
Familial male precocious puberty is an autosomal dominant disorder caused by activating pathogenic variants in the LHCGR gene (Shenker et al. 1993) while Leydig cell hypoplasia in both males and females is an autosomal recessive disorder caused by inactivating pathogenic variants in the LHCGR gene (Kremer et al. 1995; Latronico et al. 1996).
The LHCGR gene has 11 coding exons that encode the receptor for both luteinizing hormone and choriogonadotropin, which belongs to the G-protein coupled receptor family. While only missense LHCGR (activating) pathogenic variants have been found in familial male precocious puberty, genetic defects of LHCGR found to date in the spectrum of Leydig cell hypoplasia include missense, nonsense, splicing, small deletions and large deletions (Human Gene Mutation Database). A mutation hot spot has been found in exon 11, which contains the common mutation p.Asp578Gly (Laue et al. 1995).
Clinical Sensitivity - Sequencing with CNV PG-Select
In a study of 32 unrelated families affected by familial male precocious puberty, all families were found through sequencing to have a LHCGR pathogenic variant (Laue et al. 1995), which indicated a high clinical sensitivity in sequencing for this disease. Detection rate of pathogenic variants in the LHCGR gene in a large cohort of patients with Leydig cell hypoplasia is unknown in the literature because only a limited number of cases have been reported.
Testing Strategy
This test provides full coverage of all coding exons of the LHCGR gene, plus ~10 bases of flanking noncoding DNA. We define full coverage as >20X NGS reads or Sanger sequencing.
Indications for Test
Candidates for this test are patients with familial male precocious puberty or Leydig cell hypoplasia. Testing is also indicated for family members of patients who have known pathogenic variants in the LHCGR gene. This test may also be considered for the reproductive partners of individuals who carry pathogenic variants in LHCGR.
Candidates for this test are patients with familial male precocious puberty or Leydig cell hypoplasia. Testing is also indicated for family members of patients who have known pathogenic variants in the LHCGR gene. This test may also be considered for the reproductive partners of individuals who carry pathogenic variants in LHCGR.
Gene
Official Gene Symbol | OMIM ID |
---|---|
LHCGR | 152790 |
Inheritance | Abbreviation |
---|---|
Autosomal Dominant | AD |
Autosomal Recessive | AR |
X-Linked | XL |
Mitochondrial | MT |
Diseases
Name | Inheritance | OMIM ID |
---|---|---|
Gonadotropin-Independent Familial Sexual Precocity | AD | 176410 |
Leydig Cell Hypoplasia, Type I | AR | 238320 |
Citations 
- Human Gene Mutation Database (Bio-base).
- Kremer H. et al. 1995. Nature Genetics. 9: 160-4. PubMed ID: 7719343
- Latronico AC. et al. 1996. The New England Journal of Medicine. 334: 507-12. PubMed ID: 8559204
- Laue L. et al. 1995. Proceedings of the National Academy of Sciences of the United States of America. 92: 1906-10. PubMed ID: 7892197
- Shenker A. et al. 1993. Nature. 365: 652-4. PubMed ID: 7692306
- Themmen APN., Huhtaniemi IT. 2000. Endocrine Reviews. 21: 551-83. PubMed ID: 11041448
Ordering/Specimens 
Ordering Options
We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.
myPrevent - Online Ordering
- The test can be added to your online orders in the Summary and Pricing section.
- Once the test has been added log in to myPrevent to fill out an online requisition form.
- PGnome sequencing panels can be ordered via the myPrevent portal only at this time.
Requisition Form
- A completed requisition form must accompany all specimens.
- Billing information along with specimen and shipping instructions are within the requisition form.
- All testing must be ordered by a qualified healthcare provider.
For Requisition Forms, visit our Forms page
If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.
Specimen Types
Specimen Requirements and Shipping Details

ORDER OPTIONS
View Ordering Instructions1) Select Test Type
2) Select Additional Test Options
No Additional Test Options are available for this test.